SPERO THERAPEUTICS INC's ticker is SPRO and the CUSIP is 84833T103. A total of 80 filers reported holding SPERO THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.90 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $24,421 | -62.0% | 20,183 | -54.5% | 0.00% | – |
| Q2 2023 | $64,321 | +67.1% | 44,359 | +67.1% | 0.00% | – |
| Q1 2023 | $38,489 | -83.9% | 26,544 | -80.8% | 0.00% | – |
| Q4 2022 | $239,517 | -45.9% | 138,449 | -37.3% | 0.00% | – |
| Q3 2022 | $443,000 | +1007.5% | 220,986 | +308.1% | 0.00% | – |
| Q2 2022 | $40,000 | -93.2% | 54,145 | -19.3% | 0.00% | – |
| Q1 2022 | $584,000 | -84.0% | 67,084 | -70.5% | 0.00% | – |
| Q4 2021 | $3,640,000 | +73.7% | 227,366 | +99.9% | 0.00% | – |
| Q3 2021 | $2,095,000 | +57.8% | 113,748 | +19.5% | 0.00% | – |
| Q2 2021 | $1,328,000 | -34.7% | 95,158 | -31.2% | 0.00% | – |
| Q1 2021 | $2,035,000 | -62.6% | 138,283 | -50.7% | 0.00% | – |
| Q4 2020 | $5,440,000 | +476.9% | 280,556 | +232.0% | 0.00% | – |
| Q3 2020 | $943,000 | +73.0% | 84,508 | +110.0% | 0.00% | – |
| Q2 2020 | $545,000 | +365.8% | 40,250 | +263.8% | 0.00% | – |
| Q3 2019 | $117,000 | – | 11,063 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 3,932,209 | $76,246,000 | 15.85% |
| Atlas Venture Associates XI, LLC | 1,376,968 | $26,700,000 | 4.23% |
| Atlas Venture Associates IX, LLC | 1,376,968 | $26,700,000 | 4.23% |
| BVF INC/IL | 2,243,278 | $43,497,000 | 1.71% |
| AWM Investment Company, Inc. | 372,755 | $7,228,000 | 0.92% |
| Alphabet Inc. | 889,979 | $17,257,000 | 0.83% |
| Rock Springs Capital Management LP | 1,235,000 | $23,947,000 | 0.51% |
| Novo Holdings A/S | 576,702 | $11,182,000 | 0.48% |
| Artal Group S.A. | 500,000 | $9,695,000 | 0.21% |
| Granahan Investment Management | 420,320 | $8,150,000 | 0.18% |